Literature DB >> 11257357

Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses.

Z Wang1, L Hangartner, T I Cornu, L R Martin, A Zuniga, M A Billeter, H Y Naim.   

Abstract

We have genetically engineered a panel of recombinant measles viruses (rMVs) that express from various positions within the MV genome either the HN or F surface glycoproteins of mumps virus (MuV) or the env, gag or pol proteins from simian immunodeficiency virus (SIV). All rMVs were rescued from the respective antigenomic plasmid constructs; progeny viruses replicated comparably to the progenitor Edmonston B MV, but showed slight propagation retardation, which was dependent on the size and nature of the expressed proteins and on the genomic position of the inserts. All transgenes except that encoding mumps F glycoprotein were faithfully maintained and expressed even after virus amplification by 10(20). Our results suggest possible applications of rMVs as live-attenuated, multivalent vaccines against retroviruses such as SIV and HIV as well as other pathogens more distantly related to MV than MuV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257357     DOI: 10.1016/s0264-410x(00)00523-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

2.  Recombinant Newcastle disease virus as a vaccine vector.

Authors:  T Nakaya; J Cros; M S Park; Y Nakaya; H Zheng; A Sagrera; E Villar; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

4.  An immune competent mouse model for the characterization of recombinant measles vaccines.

Authors:  René R Marty; Marlyse C Knuchel; Teldja Neige Azzouz Morin; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 5.  Measles virus.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 6.  Applications and challenges of multivalent recombinant vaccines.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

7.  A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Authors:  Chantal Combredet; Valérie Labrousse; Lucile Mollet; Clarisse Lorin; Frédéric Delebecque; Bruno Hurtrel; Harold McClure; Mark B Feinberg; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

9.  Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function.

Authors:  Patricia Devaux; Roberto Cattaneo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Importance of the cytoplasmic tails of the measles virus glycoproteins for fusogenic activity and the generation of recombinant measles viruses.

Authors:  Markus Moll; Hans-Dieter Klenk; Andrea Maisner
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.